SequelSEC

Aditxt, Inc. ADTX

Pharmaceutical Preparations · CIK 0001726711 · Fiscal year ends 1231

Revenue
$14.34K
Fiscal year ended 2026-03-31
Operating income
-$18.32M
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

Aditxt, Inc. (ADTX) reported revenue of $14.34K and net income of -$53.34M for the fiscal year ended 2026-03-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Aditxt, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Aditxt, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Revenue$14.34K
Cost of revenue$11.48K
Gross profit$2.85K
Operating income-$18.32M
Net income-$53.34M
Research & development$3.03M
Weighted-average diluted sharesUnavailable
Pretax income-$53.02M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$14.94M
Selling & marketingUnavailable

Balance

Aditxt, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Cash & equivalentsUnavailable
Total assets$13.91M
Current assets$850.01K
Total liabilities$49.08M
Current liabilities$13.34M
Total equity incl. NCI-$35.17M
Temporary (mezzanine) equityUnavailable
Inventory$128.37K
Accounts receivable$11.97K
Goodwill$537.38K
Long-term debtUnavailable
Accounts payable$7.73M

Cash flow

Aditxt, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Operating cash flow-$18.55M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$20.80M
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Aditxt, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-31
Free cash flowUnavailable
Gross margin19.9%
Operating margin-127821.4%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio0.06x
Revenue YoY growth-74.1%
Net margin-372062.4%
R&D / revenue21149.6%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ADTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-18View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-03-31View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.